Developer docs
API playgroundTry for free, no card

Search company profiles

Heligenics

Full company profile

uuid0000y2e

Namestring
Heligenics
Legal namestring
Heligenics, Inc.
Websiteurl
heligenics.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Heligenics, Inc. is a Las Vegas-based biotechnology company that operates the proprietary GigaAssay™ platform, a high-throughput, high-content functional genomics system that screens hundreds of thousands of protein variants simultaneously in human cells to map variant function through its MEGA-Maps™ output. The platform uses UMI-barcoded clonal distributions to functionally characterize protein variants, chimeric constructs, and engineered biologics without physical separation, and has demonstrated 95% accuracy with 100% positive predictive value in a HER2 benchmark study. The company monetizes through four channels: licensing the GigaAssay platform to pharmaceutical and biotech firms, custom biologics co-development partnerships, data licensing through a Public Data Portal, and platform spin-offs that leverage the technology in specific therapeutic areas. Its named customer base is thin, with primary commercial engagement still in development; pipeline assets include interferon beta biobetters and biosimilars, interferon-alpha2 variants, interferon chimeras, incretin variants (GLP-1, GIP, GCG), and a HER2+ breast cancer companion diagnostic, with the October 2025 launch of Altagenics via GLD Partners establishing a replicable spin-off model for new therapeutic areas. The company is founder-controlled by CEO Martin Schiller, has received a $2.5M Nevada Knowledge Fund grant plus two NIH SBIR awards and several undisclosed funding rounds totaling roughly $11M+, and maintains a small team in the 11-50 range.

Short descriptiontext

Heligenics operates the GigaAssay platform, a high-throughput functional genomics system that screens hundreds of thousands of biologic variants in human cells to map variant function, licensing the technology and co-developing biologics with pharmaceutical and biotech partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLas Vegas, United States
HQ citystring
Las Vegas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
functional genomics platform, biologics discovery services, high-content screening, protein variant analysis, companion diagnostic tests
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical and Diagnostic Laboratories6215
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biologics Drug Discovery Platform
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Technology Licensing
TypeLicensing Royalties
Description

Licensing the proprietary GigaAssay platform to pharmaceutical and biotech companies for drug discovery applications

heligenics.com
2Custom Biologics Development
TypeProfessional Services
Description

Co-development of innovative biologics with partner organizations, creating custom biologic drug candidates tailored to partner needs

heligenics.com
3Data Licensing
TypeData Monetisation
Description

Providing access to proprietary functional datasets and variant libraries through the Public Data Portal for researchers and companies

heligenics.com
4Platform Spin-offs
TypeLicensing Royalties
Description

Launching spin-off companies (like Altagenics) that leverage the GigaAssay platform for specific therapeutic areas, with strategic and financial backing from partners like GLD Partners LP

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details1 tier
1Partnership and Licensing arrangements
ModelOtherBilling cadenceMulti-year contract
Notes

Customized partnership arrangements for pharmaceutical companies interested in co-developing biologics, licensing the GigaAssay platform, or accessing proprietary variant libraries

heligenics.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Heligenics operates a proprietary GigaAssay™ high-throughput functional genomics platform that simultaneously screens hundreds of thousands of biologic variant libraries in human cells and outputs MEGA-Maps™ of variant function. On top of the platform the company runs Custom Biologics co-development partnerships, a HER2+ breast cancer companion diagnostic, a free Public Data Portal with example datasets, and a pipeline of licensable Interferon and Incretin biologic candidates.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 95% accuracy, 100% sensitivity, 100% PPV in HER2 gain-of-function benchmark study
+4 more records
Product overview1 text field

Heligenics is a biotechnology company offering a unified platform-based approach centered on its proprietary GigaAssay™ technology and MEGA-Maps™ functional mapping system. The core offering consists of Custom Biologics services for partner co-development, a Public Data Portal for data access, and a pipeline of proprietary therapeutic assets including Interferon variants (biobetters, biosimilars, chimeras) and Incretin candidates. The company also provides a HER2+ breast cancer companion diagnostic test. All offerings leverage the GigaAssay platform's high-throughput screening of biologic variants in human cells.

Product and service9 records
1GigaAssay™ Platform
CategoryFunctional genomics screening platform
Description

Proprietary high-throughput, high-content screening platform that creates MEGA-Maps of protein variant function by simultaneously screening hundreds of thousands of biologic variants in human cells; used by pharmaceutical and biotech partners for drug discovery.

2MEGA-Maps™
CategoryFunctional genomics data products
Description

Functional mapping outputs that measure the impact of amino-acid substitutions in target proteins on molecular function or cellular processes in human cells, providing high-resolution structure–activity relationship data.

3Custom Biologics Service
CategoryBiologics co-development services
Description

Co-development partnership service that builds custom biologic drug candidates for pharma and biotech partners, including variant library construction, cell-based GigaAssay screening, and lead optimization.

4Public Data Portal
CategoryData access portal
Description

Free interactive portal offering example GigaAssay datasets for HIV Tat transcription factor and HER2 oncogene, giving researchers access to functional genomics data before commercial engagement.

5HER2+ Breast Cancer Companion Diagnostic
CategoryCompanion diagnostic
Description

First-of-its-kind precision prescription genetic test that uses GigaAssay technology to match HER2+ breast cancer patients to Tykerb, Tukysa, or Nerlynx based on tumor genetics.

6Interferon Beta Biobetters and Biosimilars Program
CategoryLicensable biologic pipeline assets
Description

Licensable pipeline assets of improved and comparable Interferon-beta biologic candidates for Multiple Sclerosis, featuring precision glycosylation, reduced immunogenicity, and EC50 comparable to reference drugs for biosimilars.

7Interferon-alpha2 Variant Program
CategoryLicensable biologic pipeline assets
Description

Licensable pipeline of more than 350 recombinant human Interferon-α2 variants with precision modifications for improved potency in cancer and immunology indications.

8Interferon Chimera Program
CategoryLicensable biologic pipeline assets
Description

Licensable dual-gene agonist biologic candidates combining multiple Interferon genes into single hybrid molecules with improved activity versus single-gene interferon-alpha2 products.

9Incretin Variants Program (GLP-1, GIP, GCG)
CategoryLicensable biologic pipeline assets
Description

Licensable pipeline of GLP-1, GIP, and GCG incretin receptor variants and multi-agonist candidates for obesity and metabolic disorders.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-05-11
Description

Collaboration to make available the functional output of Variants of Unknown Significance (VUS) throughout key portions of the ERBB2 gene through the JAX Clinical Knowledgebase (CKB). The partnership helps modernize and expand variant interpretation for key cancer genes, with benefits including identifying impact of thousands of ERBB2 mutations and testing 95% of possible mutants for functional impact in 5 months.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Public antibody/biologic discovery platform that uses high-throughput single-cell screening to identify therapeutic candidates from natural immune repertoires. Operates a similar technology-licensing and partnership-driven business model with pharma clients.

TypeDirect peer
Description

Cell engineering platform company that uses high-throughput screening and synthetic biology to develop engineered organisms and proteins, with a similar platform-licensing and spin-out (e.g., Motif FoodWorks) business model.

TypeDirect peer
Description

AI/ML-enabled drug discovery platform combining machine learning with high-throughput biology to discover and optimize therapeutic candidates, sharing Heligenics' emphasis on data-driven biologic discovery at scale.

TypeEmerging player
Description

AI protein design platform focused on engineering biologics with improved properties using machine learning models, representing a competitive AI-first approach to the same biologic optimization problem Heligenics addresses with wet-lab screening.

TypeEmerging player
Description

Generative AI platform for designing novel protein therapeutics across multiple therapeutic areas, competing for the same biologic-discovery value pool with a more computationally oriented approach.

TypeDirect peer
Description

DNA synthesis platform that enables construction of variant libraries and gene fragments at scale, providing key input technology for functional genomics screens and overlapping with Heligenics' library-screening workflow.

TypeBroad incumbent
Description

Large biopharmaceutical company with proprietary high-throughput functional genomics capabilities (Regeneron Genetics Center) and a successful track record of biologic drug discovery, representing both a potential partner and a competitor for biologic-discovery customers.

TypeBroad incumbent
Description

Major biopharmaceutical manufacturer with extensive internal biologics discovery and protein engineering capabilities (e.g., bispecific T-cell engagers), a potential large-pharma customer that could either license Heligenics' platform or build similar capabilities internally.

TypeBroad incumbent
Description

Computational chemistry and biology platform serving pharma R&D with molecular simulation and AI tools, representing an alternative in silico approach to the same drug-discovery optimization problem Heligenics addresses with wet-lab functional screening.

TypeDirect peer
Description

AI-enabled drug discovery company combining high-throughput biology, automated screening, and machine learning to build proprietary datasets for therapeutic discovery, sharing Heligenics' emphasis on data moats and platform-based discovery.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Heligenics

Biologics Drug Discovery Platformheligenics.com

Heligenics operates the GigaAssay platform, a high-throughput functional genomics system that screens hundreds of thousands of biologic variants in human cells to map variant function, licensing the technology and co-developing biologics with pharmaceutical and biotech partners.

What Heligenics does

Heligenics, Inc. is a Las Vegas-based biotechnology company that operates the proprietary GigaAssay™ platform, a high-throughput, high-content functional genomics system that screens hundreds of thousands of protein variants simultaneously in human cells to map variant function through its MEGA-Maps™ output. The platform uses UMI-barcoded clonal distributions to functionally characterize protein variants, chimeric constructs, and engineered biologics without physical separation, and has demonstrated 95% accuracy with 100% positive predictive value in a HER2 benchmark study. The company monetizes through four channels: licensing the GigaAssay platform to pharmaceutical and biotech firms, custom biologics co-development partnerships, data licensing through a Public Data Portal, and platform spin-offs that leverage the technology in specific therapeutic areas. Its named customer base is thin, with primary commercial engagement still in development; pipeline assets include interferon beta biobetters and biosimilars, interferon-alpha2 variants, interferon chimeras, incretin variants (GLP-1, GIP, GCG), and a HER2+ breast cancer companion diagnostic, with the October 2025 launch of Altagenics via GLD Partners establishing a replicable spin-off model for new therapeutic areas. The company is founder-controlled by CEO Martin Schiller, has received a $2.5M Nevada Knowledge Fund grant plus two NIH SBIR awards and several undisclosed funding rounds totaling roughly $11M+, and maintains a small team in the 11-50 range.

Heligenics firmographics

Firmographics
Name
Heligenics
Legal name
Heligenics, Inc.
Website
https://heligenics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Heligenics operates the GigaAssay platform, a high-throughput functional genomics system that screens hundreds of thousands of biologic variants in human cells to map variant function, licensing the technology and co-developing biologics with pharmaceutical and biotech partners.
Ownership category
akta.pro rank

Heligenics industry classification

Industry
Product category
Biologics Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Functional genomics platform
  • Biologics discovery services
  • High-content screening
  • Protein variant analysis
  • Companion diagnostic tests

Where Heligenics is headquartered

Location

Headquarters

HQ city
Las Vegas
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Heligenics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing: Licensing the proprietary GigaAssay platform to pharmaceutical and biotech companies for drug discovery applications
  2. Custom Biologics Development: Co-development of innovative biologics with partner organizations, creating custom biologic drug candidates tailored to partner needs
  3. Data Licensing: Providing access to proprietary functional datasets and variant libraries through the Public Data Portal for researchers and companies
  4. Platform Spin-offs: Launching spin-off companies (like Altagenics) that leverage the GigaAssay platform for specific therapeutic areas, with strategic and financial backing from partners like GLD Partners LP

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPartnership and Licensing arrangements

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Heligenics product offering

Product offering

Core offering

Heligenics operates a proprietary GigaAssay™ high-throughput functional genomics platform that simultaneously screens hundreds of thousands of biologic variant libraries in human cells and outputs MEGA-Maps™ of variant function. On top of the platform the company runs Custom Biologics co-development partnerships, a HER2+ breast cancer companion diagnostic, a free Public Data Portal with example datasets, and a pipeline of licensable Interferon and Incretin biologic candidates.

Product overview

Heligenics is a biotechnology company offering a unified platform-based approach centered on its proprietary GigaAssay™ technology and MEGA-Maps™ functional mapping system. The core offering consists of Custom Biologics services for partner co-development, a Public Data Portal for data access, and a pipeline of proprietary therapeutic assets including Interferon variants (biobetters, biosimilars, chimeras) and Incretin candidates. The company also provides a HER2+ breast cancer companion diagnostic test. All offerings leverage the GigaAssay platform's high-throughput screening of biologic variants in human cells.

Differentiator

Problem solved

Functional benefit

Products and services

  • GigaAssay™ Platform Proprietary high-throughput, high-content screening platform that creates MEGA-Maps of protein variant function by simultaneously screening hundreds of thousands of biologic variants in human cells; used by pharmaceutical and biotech partners for drug discovery.
  • MEGA-Maps™ Functional mapping outputs that measure the impact of amino-acid substitutions in target proteins on molecular function or cellular processes in human cells, providing high-resolution structure–activity relationship data.
  • Custom Biologics Service Co-development partnership service that builds custom biologic drug candidates for pharma and biotech partners, including variant library construction, cell-based GigaAssay screening, and lead optimization.
  • Public Data Portal Free interactive portal offering example GigaAssay datasets for HIV Tat transcription factor and HER2 oncogene, giving researchers access to functional genomics data before commercial engagement.
  • HER2+ Breast Cancer Companion Diagnostic First-of-its-kind precision prescription genetic test that uses GigaAssay technology to match HER2+ breast cancer patients to Tykerb, Tukysa, or Nerlynx based on tumor genetics.
  • Interferon Beta Biobetters and Biosimilars Program Licensable pipeline assets of improved and comparable Interferon-beta biologic candidates for Multiple Sclerosis, featuring precision glycosylation, reduced immunogenicity, and EC50 comparable to reference drugs for biosimilars.
  • Interferon-alpha2 Variant Program Licensable pipeline of more than 350 recombinant human Interferon-α2 variants with precision modifications for improved potency in cancer and immunology indications.
  • Interferon Chimera Program Licensable dual-gene agonist biologic candidates combining multiple Interferon genes into single hybrid molecules with improved activity versus single-gene interferon-alpha2 products.
  • Incretin Variants Program (GLP-1, GIP, GCG) Licensable pipeline of GLP-1, GIP, and GCG incretin receptor variants and multi-agonist candidates for obesity and metabolic disorders.

Quantifiable outcome

  • 95% accuracy, 100% sensitivity, 100% PPV in HER2 gain-of-function benchmark study
  • +4 more outcomes

Companies that use Heligenics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Heligenics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Heligenics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • The Jackson Laboratory (JAX)coreStrategic or Co-development Partner · 11 May 2021Collaboration to make available the functional output of Variants of Unknown Significance (VUS) throughout key portions of the ERBB2 gene through the JAX Clinical Knowledgebase (CKB). The partnership helps modernize and expand variant interpretation for key cancer genes, with benefits including identifying impact of thousands of ERBB2 mutations and testing 95% of possible mutants for functional impact in 5 months.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Heligenics competitors and assessment

Company assessment

Direct peers

  • AbCellera Biologics: Public antibody/biologic discovery platform that uses high-throughput single-cell screening to identify therapeutic candidates from natural immune repertoires. Operates a similar technology-licensing and partnership-driven business model with pharma clients.
  • Ginkgo Bioworks: Cell engineering platform company that uses high-throughput screening and synthetic biology to develop engineered organisms and proteins, with a similar platform-licensing and spin-out (e.g., Motif FoodWorks) business model.
  • Insitro: AI/ML-enabled drug discovery platform combining machine learning with high-throughput biology to discover and optimize therapeutic candidates, sharing Heligenics' emphasis on data-driven biologic discovery at scale.
  • Twist Bioscience: DNA synthesis platform that enables construction of variant libraries and gene fragments at scale, providing key input technology for functional genomics screens and overlapping with Heligenics' library-screening workflow.
  • Recursion Pharmaceuticals: AI-enabled drug discovery company combining high-throughput biology, automated screening, and machine learning to build proprietary datasets for therapeutic discovery, sharing Heligenics' emphasis on data moats and platform-based discovery.

Emerging players

  • Cradle Bio: AI protein design platform focused on engineering biologics with improved properties using machine learning models, representing a competitive AI-first approach to the same biologic optimization problem Heligenics addresses with wet-lab screening.
  • Generate Biomedicines: Generative AI platform for designing novel protein therapeutics across multiple therapeutic areas, competing for the same biologic-discovery value pool with a more computationally oriented approach.

Broad incumbents

  • Regeneron Pharmaceuticals: Large biopharmaceutical company with proprietary high-throughput functional genomics capabilities (Regeneron Genetics Center) and a successful track record of biologic drug discovery, representing both a potential partner and a competitor for biologic-discovery customers.
  • Amgen: Major biopharmaceutical manufacturer with extensive internal biologics discovery and protein engineering capabilities (e.g., bispecific T-cell engagers), a potential large-pharma customer that could either license Heligenics' platform or build similar capabilities internally.
  • Schrödinger, Inc. Computational chemistry and biology platform serving pharma R&D with molecular simulation and AI tools, representing an alternative in silico approach to the same drug-discovery optimization problem Heligenics addresses with wet-lab functional screening.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Heligenics social profiles

Digital presence

Heligenics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Heligenics leadership team

Management profile

Number of profiles

Profiles13 records

Heligenics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Heligenics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Heligenics

What does Heligenics do?

Heligenics operates a proprietary GigaAssay™ high-throughput functional genomics platform that simultaneously screens hundreds of thousands of biologic variant libraries in human cells and outputs MEGA-Maps™ of variant function. On top of the platform the company runs Custom Biologics co-development partnerships, a HER2+ breast cancer companion diagnostic, a free Public Data Portal with example datasets, and a pipeline of licensable Interferon and Incretin biologic candidates.

Is Heligenics a public or private company?

Heligenics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Heligenics founded?

Heligenics was founded in 2016. It employs 11 to 50 people.

Where is Heligenics based?

Heligenics is headquartered in Las Vegas, United States, in the North America region.

How does Heligenics make money?

Four revenue lines are on record. Technology Licensing is the primary driver. The others are custom Biologics Development, data Licensing and platform Spin-offs.

Who are Heligenics's main competitors?

Direct peers on record are AbCellera Biologics, Ginkgo Bioworks, Insitro, Twist Bioscience and Recursion Pharmaceuticals. Emerging players are Cradle Bio and Generate Biomedicines. Broad incumbents are Regeneron Pharmaceuticals, Amgen and Schrödinger, Inc..

Does Heligenics have an API?

No public API is recorded for Heligenics.

What industry is Heligenics in?

Heligenics's product category is Biologics Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireGLD Partners LP Launches New Biotech Company, Altagenics, to Accelerate Drug Discovery for Muscle-Wasting DiseasesGLD Partners LP announced the launch of Altagenics, a new biotechnology company focused on drug discovery for muscle-wasting diseases, leveraging Heligenics' proprietary GigaAssay™ platform. The company will initially target sarcopenia and cachexia using next-generation functional genomics technology capable of testing hundreds of thousands of protein variants in parallel. This venture represents GLD Partners' strategy to build platform-driven biotech companies, with plans to replicate this scalable model across additional therapeutic areas.PR NewswireHigh Content Screening for Biologics a Revolutionary Approach to Drug DiscoveryHeligenics, Inc. announced the application of its GigaAssay technology to screen 100,000 biologic drugs, specifically focusing on bi-functional Interferon chimeras and custom variants for treating autoimmune diseases, viral infections, and cancers. The company claims this high-content screening approach allows for precision glycosylation and hybrid creation, establishing a new standard in drug discovery beyond traditional small molecule methods.PR NewswireA Breakthrough in Interferon-based Therapies for Multiple SclerosisHeligenics, Inc. announced that its GigaAssay drug development platform analyzed approximately 5,000 genetic variants in the interferon beta gene and identified 70 promising biobetter sequence leads and 1,300 biosimilar sequence leads for Multiple Sclerosis therapy. The company stated this represents a breakthrough in applying High Content Screening technology to biologic drugs such as interferons. Heligenics is actively seeking pharmaceutical partnership opportunities to advance the Interferon Beta Biobetters to market and collaborate on additional biological drug projects.SecSEC FORM DHeligenics, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing indicates that the company raised $2,160,000 from 12 investors for equity securities.PR NewswireInternational Innovation Center @ Vegas Announces New Tenant at Satellite Location: Las Vegas-Based Heligenics, Inc.The International Innovation Center @ Vegas announced Heligenics, Inc. as a new tenant at its satellite location at 833 Las Vegas Blvd. North, with the city of Las Vegas approving a 1,300 square foot lease. The main IIC@Vegas location at 300 S. 4th Street is fully occupied with ten tenants, prompting the city to expand via the satellite location. Heligenics focuses on improving drug development and clinical trial design through its GigaAssay technology, which measures the functional significance of human genome mutations to convert generic drugs into targeted precision medicines.